Advancing
a New Front
in the War against Cancer

Provectus Biopharmaceuticals is
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects


PV-10

An Investigational Drug for Cancer

PH-10

An Investigational Drug for Psoriasis and Atopic Dermatitis

IN THE MEDIA

May 20, 2015

Asia Biotech Invest Conference Presentation Slides Available

Provectus presented at the Asia Biotech Invest Conference in Hong Kong on May 20, 2015 at 10:00 AM HKT.

May 19, 2015

Provectus taking novel path to treat cancer

A recent BioTuesday article discusses Provectus' novel approach of using physical chemistry and a different basis for the mechanism of action of its Rose Bengal based investigational anti-cancer agents, including PV-10, currently in phase 3 clinical testing.

May 19, 2015

Intralesional therapy for metastatic melanoma - ModernMedicine

Kate's Foundation created a news brief on last week's Modern Medicine/Dermatology Times article on treating metastatic melanoma with investigational drug PV-10.

May 15, 2015

Intralesional therapy for metastatic melanoma

An article appearing in Dermatology Times titled "Intralesional therapy for metastatic melanoma" discusses the "bystander" effect seen in clinical testing of intralesional PV-10 for melanoma and clinical evidence from studies at Moffitt Cancer Center that intralesional PV-10 induces a systemic immune response.

May 14, 2015

Audio: Dr. Sanjiv Agarwala Interviewed on iHeart Radio 24/7 News

In support of Melanoma Awareness Month, an interview of Dr. Sanjiv Agarwala was aired on iHeart Radio 24/7 News on May 7, 2015.

May 14, 2015

Audio: PV-10 Phase 3 Enrollment Info Aired on WAEB in Allentown, PA

Beginning May 4, 2015, an ad was aired on WAEB NewsRadio 790 in Allentown, PA informing the community that Provectus is seeking patients for the phase 3 trial of PV-10 for melanoma and that patients may now enrol at St. Luke's University Hospital and Health Network in Bethlehem, PA.

May 14, 2015

Audio: Dr. Sanjiv Agarwala Discusses Melanoma on Talk with Audrey

Audrey Adams recently interviewed Sanjiv Agarwala, MD on the syndicated radio program Talk With Audrey.

May 14, 2015

Commentary: Intralesional Melanoma Treatments Are Ready for Prime Time

A DDN News article discusses the intralesional drug candidates, including PV-10, that are currently being investigated for advanced melanoma treatment.

May 7, 2015

Webcast: Q1 2015 Quarterly Business Update Conference Call

Provectus will hold its quarterly business update conference call at 4 p.m. (EDT) May 7, 2015 to provide a business update on PV-10 and PH-10 to the investment community and answer questions from investors.

May 7, 2015

May is National Melanoma Skin Cancer Prevention Month

In recognition of National Melanoma Skin Cancer Prevention Month, Melanoma News Today reports on promising new strategies for the treatment of melanoma, including PV-10.

May 4, 2015

BioCentury Updates Clinical Status for Provectus

The Clinical News section of the April 27, 2015 edition of BioCentury included a clinical status update for Provectus reporting the initiation of a phase 3 trial of PV-10 for melanoma.

May 4, 2015

Novel Therapies Are Giving New Hope for Patients with Advanced Melanoma

A Newswise article announces that Dr. Sanjiv Agarwala is available for media interview to discuss cutting-edge treatments that represent the recent surge in research aimed at battling late stage melanoma.

April 22, 2015

Provectus prioritizes pharma partners with clinical-stage PD1/PDL1s

A BioPharm Insight article reports on Provectus efforts to partner with companies having PD1 or PDL1 inhibitor agents in late-stage development, noting the recently approved joint patent with Pfizer covering the use of PV-10 in combination with systemic inhibitors of immune system regulation.

April 22, 2015

Provectus Biopharmaceuticals, Pfizer Receive Patent Allowance for Use of PV-10 in Combination with Systemic Immunotherapy Agents in Treatment of Cancer

Dermwire covers news that Provectus an Pfizer have received allowance from the FDA for a jointly held patent protecting the use of PV-10 in combination with systemic inhibitors of immune system regulation.

April 17, 2015

Audio Recording of Provectus Panel Discussion Now Available

An audio recording of Provectus' panel discussion on Thursday, April 9, 2015 at The Harvard Club of New York City is now available.

April 16, 2015

Provectus Opens Phase 3 Trial Enrollment for Investigational Melanoma Agent

Dermwire covers news that Provectus has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma.

April 15, 2015

Presentation Slides Available from ChinaBio Partnering Forum 2015

Slides are now available from Provectus' presentation at ChinaBio Partnering Forum 2015.

April 13, 2015

Growth Capital Expo Presentation Slides and Webcast Available

Webcast and slides from Provectus' presentation at Growth Capital Expo 2015 are available for download.

April 13, 2015

Phase 3 trial to compare PV-10 with chemotherapy in stage III melanoma

An article appearing on Healio discusses the Phase 3 trial of PV-10 for locally advanced cutaneous melanoma that is soon to begin recruiting, and includes quotes from Dr. Sanjiv Agarwala regarding trial design.

April 10, 2015

Trials in Progress: Intralesional PV-10 vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma

A poster presentation at the HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting presents an overview of study PV-10-MM-31, Provectus' Phase 3 trial of PV-10 for locally advanced cutaneous melanoma.

more...

PRESS RELEASES

May 27, 2015

Provectus Biopharmaceutical's Abstract Accepted for Poster Presentation at 5th European Post-Chicago Melanoma / Skin Cancer Meeting

Provectus today announced that the presentation committee of the 5th European Post-Chicago Melanoma / Skin Cancer Meeting has accepted its abstract titled "Trials in Progress: Intralesional Rose Bengal vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma."

May 18, 2015

Provectus Biopharmaceuticals Extends for Additional 60 Days Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-Think Pharmaceutical Co., Ltd

Provectus today announced that it had extended for an additional 60 days its Memorandum of Understanding with with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK"), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group.

May 14, 2015

Provectus Biopharmaceuticals' Poster Presentation on PV-10 Clinical Data from Phase 1 Study for Cancers of the Liver Scheduled for Thursday, July 2, 2015 at 17th World Congress on Gastrointestinal Cancer

Provectus announced today that the abstract titled, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver," to be presented at the European Society for Medical Oncology's 17th World Congress on Gastrointestinal Cancer, is scheduled for Thursday, July 2, 2015 from 10:30 to 11:00 a.m. and 4:55 to 5:25 p.m. local time. Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Health Network, Bethlehem, PA, will be the presenter.

May 8, 2015

Provectus Biopharmaceuticals Updates Market on Business Developments

Provectus provided the market with a business update in its quarterly investor conference call held on Thursday, May 7, 2015, that addresses several matters in conjunction with the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.

May 7, 2015

Provectus Biopharmaceuticals Reports First Quarter Financial Results

Provectus today announced its results of operations and financial condition for the first quarter ended March 31, 2015.

May 5, 2015

Provectus Biopharmaceuticals's Novel Synthesis Patent Application Allowed by European Patent Office, Patent Issued by Japan

Provectus announced that it has received notification of allowance from the European Patent Office for its patent application protecting the synthetic process used to produce the small molecule Rose Bengal, the active pharmaceutical ingredient (API) in PV-10, the 'Company's lead oncology drug candidate. At the same time, the Japanese Patent Office has issued a patent for the same intellectual property.

April 30, 2015

Provectus Biopharmaceuticals' Abstract on Liver Cancer Accepted for Poster Presentation at European Society for Medical Oncology's 17th World Congress on Gastrointestinal Cancer

Provectus announced today that the European Society for Medical Oncology (ESMO) has accepted the Company's abstract, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver," for poster presentation at the ESMO 17th World Congress on Gastrointestinal Cancer.

April 29, 2015

Provectus Biopharmaceuticals Will Hold Its Quarterly Business Update Conference Call at 4 PM Eastern, Thursday, May 7, 2015

Provectus announced today that it will hold its quarterly business update conference call at 4 pm Eastern Daylight Time, on Thursday, May 7, 2015.

April 27, 2015

Provectus Biopharmaceuticals To Present at Asia Biotech Invest 2015 Conference Wednesday, May 20, 2015, Hong Kong

Provectus announced today that it will present at the Asia Biotech Invest 2015 Conference, on Wednesday, May 20, 2015, at 10 am local time.

April 20, 2015

Pfizer and Provectus Biopharmaceuticals Receive Patent Allowance for Use of PV-10 in Combination with Systemic Immunotherapy Agents in Treatment of Cancer

Provectus announced today that it has received from the US Patent and Trademark Office a Notice of Allowance for a joint patent application made with Pfizer, Inc. The patent will protect use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver.

April 15, 2015

Provectus Biopharmaceuticals Opens Patient Enrollment; Begins Phase 3 International FDA Comparative Clinical Trial of PV-10 for Melanoma

Provectus enters phase 3 and has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma.

April 8, 2015

Provectus Biopharmaceuticals to Present at 7th Annual International Partnering Conference, ChinaBio Partnering Forum 2015, Shanghai, China

Provectus announced today that it will present at the 7th Annual International Partnering Conference, ChinaBio Partnering Forum 2015, in Shanghai, China.

April 7, 2015

Provectus Biopharmaceuticals' Data on PV-10 to Be Presented at HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting

Provectus announced today that Dr. Sanjiv Agarwala will present data on PV-10, the Company's novel investigational drug for cancer, at the HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting on Friday, April 10, 2015 at the Sheraton New York Times Square Hotel.

April 2, 2015

Provectus Biopharmaceuticals Will Present at the Growth Capital Expo, Las Vegas at 1 pm PDT on Monday April 13, 2015

Provectus announced today that it will present at the Growth Capital Expo at 1 pm PDT on Monday, April 13, 2015. The Expo is being held at Caesars Palace, April 12-14, 2015.

March 20, 2015

Provectus Biopharmaceuticals Will Present at the 12th Annual BIO Asia International Conference Wednesday, March 25, 2015

Provectus announced today that it will present at the 12th Annual BIO Asia International Conference, taking place on March 24th and 25th at the Grand Hyatt in Tokyo, Japan.

March 16, 2015

Provectus Biopharmaceuticals' Amended Protocol of PV-10 for Phase 3 Study as Treatment for Melanoma Now Available Online

Provectus announced today that the amended protocol for its phase 3 study of PV-10 as a treatment for melanoma is now available at: http://clinicaltrials.gov/ct2/show/study/NCT02288897. The Company does not require additional review from the U.S. Food and Drug Administration(the "FDA") to start the phase 3 study, and has begun the process of gaining approval from the Institutional Review Board (IRB) of each individual site for the amended protocol.

March 12, 2015

Provectus Biopharmaceuticals Updates Market on Business Developments

Provectus today provides the market with a business update that addresses several matters.

March 12, 2015

Provectus Biopharmaceuticals Awarded PH-10 Patent by U.S. Patent and Trademark Office

Provectus announced today that it has received U.S. Patent No. 8,974,363 from the United States Patent and Trademark Office (USPTO).

March 12, 2015

Provectus Biopharmaceuticals, Inc. Reports Fourth Quarter and Year End 2014 Results

Provectus today announced its results of operations and financial condition for the fourth quarter and year ended December 31, 2014.

February 24, 2015

Provectus Biopharmaceuticals Will Hold Its 2014 Year-End Quarterly Business Update Conference Call at 4 PM Eastern, Thursday, March 12, 2015

Provectus announced today that it will hold its year-end quarterly business update conference call at 4 pm Eastern Daylight Time, on Thursday, March 12, 2015.

more...